Royalty Report: Drugs, Therapeutic, Disease – Collection: 240459

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Arthritis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 240459

License Grant
The Taiwan Licensor granted the Taiwan Licensee non-exclusive licensing rights to use, modify and manufacture BEL-DLS03, an API designed to treat rheumatoid arthritis, and its analysis platform for therapeutic and dietary purposes.  In accordance with the Licensor BLI-1007 License Agreement and its Amendment, in 2016 the License became an exclusive licensing right to use patent of BEL-DLS03 and the manufacturing method.
License Property
BEL-DLS03 Patent, an API designed to treat rheumatoid arthritis, and its analysis platform for therapeutic and dietary purposes.
Field of Use
The Licensee was conducting preclinical studies of BEL-DLS03, which is the API for drug candidate BLI-1007 for Rheumatoid Arthritis.

IPSCIO Record ID: 240458

License Grant
The Taiwan Licensee obtained from the Taiwan Licensor the global rights to BEL-DLS01, an API intended to treat inflammatory bowel diseases, and its surrounding proprietary information and platforms to develop, modify, manufacture, distribute and sell pharmaceutical products.
License Property
Investigational drugs that are designed for the treatment of autoimmune diseases, including BLI-1006 to treat inflammatory bowel disease.
Field of Use
With BEL-DLS01 as the API, the Taiwan Licensee is developing BLI-1006 to treat inflammatory bowel disease.

IPSCIO Record ID: 231728

License Grant
The Licensor granted the Bermudan Licensee an exclusive, sublicensable, worldwide license to certain intellectual property rights to make, use, develop and commercialize mavrilimumab. a human monoclonal antibody for the treatment of rheumatoid arthritis.
License Property
The Licensor also granted reference rights to relevant manufacturing and regulatory documents and existing supply of mavrilimumab drug substance and product.
Field of Use
The Bermudan Licensee is obligated to use commercially reasonable efforts to develop and commercialize the licensed products.  The investigational drug may be used as a rheumatoid arthritis treatment.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.